RecruitingEarly Phase 1NCT04449198
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
Sponsor
Augusta University
Enrollment
24 participants
Start Date
Oct 14, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Men and premenopausal women
- All races
- Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)
Exclusion Criteria6
- Clinical diagnosis of hepatic, cardiovascular, or renal disease
- Uncontrolled diabetes (HbA1C \>12%)
- Diabetic complications (i.e. neuropathy)
- Uncontrolled hypertension (\>140/90 mm Hg on therapy)
- Pregnancy
- Use of vasoactive medications
Interventions
DRUGResveratrol
500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
OTHERPlacebo
placebo for 12 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04449198
Related Trials
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
NCT063246044 locations
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
NCT060148791 location
Intervention for Children With Type 1 Diabetes Targeting Gut Microbes
NCT061987251 location
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
NCT072121791 location
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
NCT0706157411 locations